Influence of gut bacteria on type 2 diabetes: Mechanisms and therapeutic strategy

被引:3
作者
Wen, Xue [1 ]
Qi, Lu-Ming [1 ]
Zhao, Kui [2 ]
机构
[1] Chengdu Univ Tradit Chinese Med, Coll Hlth & Rehabil, Chengdu 610000, Sichuan, Peoples R China
[2] Southwest Forestry Univ, Coll Mat & Chem Engn, 300 White Dragon Temple, Kunming 650224, Yunnan, Peoples R China
关键词
Type; 2; diabetes; Intestinal microbiome; Intestinal axis; Biological pathways; Treatment; Short-chain fatty acids; P-CRESYL SULFATE; INSULIN SENSITIVITY; INDIGENOUS BACTERIA; MICROBIOTA; MODULATION; PROBIOTICS; RECEPTOR; OBESITY;
D O I
10.4239/wjd.v16.i1.100376
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The onset and progression of type 2 diabetes mellitus (T2DM) are strongly associated with imbalances in gut bacteria, making the gut microbiome a new potential therapeutic focus. This commentary examines the recent publication in World Journal of Diabetes. The article explores the association between T2DM and gut microbiota, with a focus on the pathophysiological changes related to dysbiosis. It proposes innovative microbiome-targeted therapeutic strategies and evaluates the challenges and future directions of such approaches. This editorial summarizes the key points of their discussion of the role of the gut microbiome in T2DM and elaborates on the influence of specific gut microbial species on the disease through the host-microbiota metabolic axis. It provides new insights for future research on gut-microbiota-based interventions for T2DM.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Neprilysin inhibition: a new therapeutic option for type 2 diabetes?
    Esser, Nathalie
    Zraika, Sakeneh
    DIABETOLOGIA, 2019, 62 (07) : 1113 - 1122
  • [22] On the role of gut bacteria and infant diet in the development of autoimmunity for type 1 diabetes
    Hanninen, Arno L. M.
    Toivonen, Raine K.
    DIABETOLOGIA, 2015, 58 (09) : 2195 - 2196
  • [23] The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus
    Kootte, R. S.
    Vrieze, A.
    Holleman, F.
    Dallinga-Thie, G. M.
    Zoetendal, E. G.
    de Vos, W. M.
    Groen, A. K.
    Hoekstra, J. B. L.
    Stroes, E. S.
    Nieuwdorp, M.
    DIABETES OBESITY & METABOLISM, 2012, 14 (02) : 112 - 120
  • [24] Evolution of the non-insulin therapeutic strategy in type 2 diabetes
    Vatier, C.
    Bourcigaux, N.
    REVUE DE MEDECINE INTERNE, 2023, 44 (10): : 561 - 566
  • [25] Type 2 diabetes mellitus: Which place for thiazolidinediones in the therapeutic strategy?
    Halimi, S
    DIABETES & METABOLISM, 2001, 27 (02) : 287 - 293
  • [26] Wholegrain fermentation affects gut microbiota composition, phenolic acid metabolism and pancreatic beta cell function in a rodent model of type 2 diabetes
    Costabile, Adele
    Corona, Giulia
    Sarnsamak, Kittiwadee
    Atar-Zwillenberg, Daphna
    Yit, Chesda
    King, Aileen J.
    Vauzour, David
    Barone, Monica
    Turroni, Silvia
    Brigidi, Patrizia
    Hauge-Evans, Astrid C.
    FRONTIERS IN MICROBIOLOGY, 2022, 13
  • [27] Oxidative stress and type 2 diabetes: a review of lactic acid bacteria as potential prophylactic and therapeutic interventions
    Ren, Siheng
    Wang, Juan
    Wang, Yuxi
    Luo, Qian
    Pu, Wei
    Meng, Xiao
    Liu, Shukun
    FOOD SCIENCE AND BIOTECHNOLOGY, 2025, : 2403 - 2416
  • [28] Indolepropionic Acid, a Gut Bacteria-Produced Tryptophan Metabolite and the Risk of Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
    Sehgal, Ratika
    de Mello, Vanessa D.
    Mannisto, Ville
    Lindstrom, Jaana
    Tuomilehto, Jaakko
    Pihlajamaki, Jussi
    Uusitupa, Matti
    NUTRIENTS, 2022, 14 (21)
  • [29] Role of gut microbiota in type 2 diabetes pathophysiology
    Gurung, Manoj
    Li, Zhipeng
    You, Hannah
    Rodrigues, Richard
    Jump, Donald B.
    Morgun, Andrey
    Shulzhenko, Natalia
    EBIOMEDICINE, 2020, 51
  • [30] The Gut Microbiome as a Target for the Treatment of Type 2 Diabetes
    Aydin, Omrum
    Nieuwdorp, Max
    Gerdes, Victor
    CURRENT DIABETES REPORTS, 2018, 18 (08)